440 related articles for article (PubMed ID: 32779341)
1. Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
Kabeerdoss J; Danda D
Int J Rheum Dis; 2020 Aug; 23(8):998-1008. PubMed ID: 32779341
[TBL] [Abstract][Full Text] [Related]
2. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
[TBL] [Abstract][Full Text] [Related]
3. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
Misra DP; Agarwal V; Gasparyan AY; Zimba O
Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
[TBL] [Abstract][Full Text] [Related]
4. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
Bugatti S; De Stefano L; Bobbio-Pallavicini F; Montecucco C
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33087414
[No Abstract] [Full Text] [Related]
5. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
6. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
Sun X; Ni Y; Zhang M
Emerg Microbes Infect; 2020 Dec; 9(1):830-832. PubMed ID: 32338155
[TBL] [Abstract][Full Text] [Related]
7. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Quiros Roldan E; Biasiotto G; Magro P; Zanella I
Pharmacol Res; 2020 Aug; 158():104904. PubMed ID: 32430286
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Dima A; Jurcut C; Arnaud L
Joint Bone Spine; 2021 May; 88(3):105143. PubMed ID: 33515791
[TBL] [Abstract][Full Text] [Related]
9. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.
Alqatari S; Nemer A; Hasan M; Bukhari R; Al Argan R; Al Khafaji D; Alwaheed A; Alzaki A; Al-Wazza M; Al Warthan S; Al Saeed A; Albeladi F; Almeer H; AlSulaiman R; Abu Quren A
J Med Life; 2023 Jun; 16(6):873-882. PubMed ID: 37675163
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
[TBL] [Abstract][Full Text] [Related]
12. [COVID-19: treatment strategies of German-speaking pediatric rheumatologists : Results of an online survey].
Janda A; Schuetz C; Heeg M; Minden K; Hedrich CM; Kallinich T; Hinze C; Schulz A; Speth F
Z Rheumatol; 2020 Sep; 79(7):710-717. PubMed ID: 32809050
[TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
Ferreira A; Oliveira-E-Silva A; Bettencourt P
J Med Virol; 2021 Feb; 93(2):755-759. PubMed ID: 32644224
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease.
Fernandez-Ruiz R; Paredes JL; Niewold TB
Transl Res; 2021 Jun; 232():13-36. PubMed ID: 33352298
[TBL] [Abstract][Full Text] [Related]
16. Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
Kardeş S; Kuzu AS; Pakhchanian H; Raiker R; Karagülle M
Clin Rheumatol; 2021 May; 40(5):2047-2055. PubMed ID: 33130946
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Licciardi F; Giani T; Baldini L; Favalli EG; Caporali R; Cimaz R
Pediatr Rheumatol Online J; 2020 Apr; 18(1):35. PubMed ID: 32321540
[TBL] [Abstract][Full Text] [Related]
18. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment.
Shah S; Danda D; Kavadichanda C; Das S; Adarsh MB; Negi VS
Rheumatol Int; 2020 Oct; 40(10):1539-1554. PubMed ID: 32666137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
